

PB - A novel drug for chronic respiratory and skin diseases

Bernhard Ryffel, MD, PhD, Head of pharmacology
Franz G. Bucher, CEO, PhenoTec AG, Zug, Switzerland

Project summary

PB is a novel anti-inflammatory butyrate derivative to treat chronic inflammatory lung and skin diseases. This claim is based on preclinical data showing strong inhibition of COPD, asthma, lung fibrosis and psoriasis. Experimental pharmacological and toxicological studies need to be finalised for registration to start phase I clinical development and licensing. PB is IP protected and easy to manufacture.

The pharmacological profile of PB and therapeutic potential

- **PB** is an orally active derivative of phenyl-butyrate inhibiting inflammation with a sustained pharmacological action.
- **PB** is highly active in human models of chronic lung inflammation such COPD, severe asthma, lung fibrosis and in skin inflammation in mice and in human cells.
- **PB** acts via G-coupled receptor GRP109A inhibiting inflammasome activation.
- **PB** is well tolerated in rodents and in man with no adverse effects and is patent protected in Europe and Japan.
- **PB** synthesis for a large scale production is in expensive and fully established

The aim is to consolidate the preclinical data on PB for clinical registration.